Hangzhou Converd Co., Ltd.
Hangzhou Converd Co., Ltd.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer | DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Infections, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, milker's nodule, neoplasm, pancreas disorder, pancreatic neoplasm, vaccinia, viral infectious disease | Recruiting | Phase 2 | 2026-02-27 | NCT07006077 | |
| Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors | Advanced Solid Tumors | Active, not recruiting | Phase 1 | 2026-02-27 | NCT05914376 | |
| A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors. | Advanced Solid Tumors | Recruiting | Not applicable | 2025-09-22 | NCT07185243 |